المؤلفون: Bronte G., Petracci E., De Matteis S., Canale M., Zampiva I., Priano I., Cravero P., Andrikou K., Burgio M. A., Ulivi P., Delmonte A., Crino L.

المساهمون: Bronte, G., Petracci, E., De Matteis, S., Canale, M., Zampiva, I., Priano, I., Cravero, P., Andrikou, K., Burgio, M. A., Ulivi, P., Delmonte, A., Crino, L.

مصطلحات موضوعية: myeloid-derived suppressive cells, primary resistance, immunotherapy, non-small cell lung cancer, immune checkpoint inhibitors

الوصف: Background: Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC) patients. Some patients experience primary resistance to immunotherapy. Currently, we lack a marker of resistance to immunotherapy. Myeloid-derived suppressive-like cells (MDSCs) can reduce tumor response rate and survival outcomes. Methods: This is an exploratory prospective observational study on metastatic NSCLC patients starting immunotherapy. Baseline peripheral blood samples were collected. Monocytic (M)-MDSCs were analyzed by flow cytometry. The main clinical outcomes were tumor response, progression-free survival (PFS), and overall survival (OS). The association between MDSC levels and tumor response was assessed. The association of PFS with OS was investigated using the Kaplan–Meier method and the Cox proportional hazards model. Results: Twenty-two patients were included. The median M-MDSC value was higher in patients with progressive disease than patients with stable disease or partial response, p = 0.045. The median MDSC value in the overall population was 1.9. We found worse PFS (HR = 2.51; p = 0.046) and OS (HR = 2.68; p = 0.042) in patients with M-MDSC values higher than the median. Conclusions: In this exploratory analysis, high M-MDSC levels are strongly associated with primary resistance to immunotherapy. If validated in larger studies, MDSC levels in blood samples could help to select NSCLC patients for higher benefit from immunotherapy.

وصف الملف: STAMPA

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/35493483; info:eu-repo/semantics/altIdentifier/wos/WOS:000808056100001; volume:13; firstpage:866561-1; lastpage:866561-10; numberofpages:10; journal:FRONTIERS IN IMMUNOLOGY; https://hdl.handle.net/11392/2542131Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85128855356; https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.866561/fullTest

الإتاحة: https://doi.org/10.3389/fimmu.2022.866561Test
https://hdl.handle.net/11392/2542131Test

المؤلفون: Zanelli, S., Fiorio, E., Zampiva, I., Zacchi, F., Borghesani, G., Giontella, E., Parolin, V., Biondani, P., Zuliani, S., Dieci, M.V., Mioranza, E., Zorzi, M., Conti, M., Gibellini, D., Verlato, G., Milella, M.

المساهمون: Horizon 2020, Ministero dell'Istruzione dell'Universita e della Ricerca, Fondazione Cariverona

المصدر: Annals of Oncology ; volume 33, issue 6, page 661-663 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2022.02.227Test
https://api.elsevier.com/content/article/PII:S0923753422003635?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422003635?httpAccept=text/plainTest

المؤلفون: Guarneri V., Bassan F., Zagonel V., Milella M., Zaninelli M., Cattelan A. M., Vianello A., Gori S., Aprile G., Azzarello G., Chiari R., Favaretto A., Oliani C., Scola A., Pastorelli D., Mandara M., Zustovich F., Bernardi D., Chiarion-Sileni V., Morandi P., Toso S., Di Liso E., Ziampiri S., Caccese M., Zampiva I., Puccetti O., Celestino M., Dieci M. V., Conte P.

المساهمون: Guarneri, V., Bassan, F., Zagonel, V., Milella, M., Zaninelli, M., Cattelan, A. M., Vianello, A., Gori, S., Aprile, G., Azzarello, G., Chiari, R., Favaretto, A., Oliani, C., Scola, A., Pastorelli, D., Mandara, M., Zustovich, F., Bernardi, D., Chiarion-Sileni, V., Morandi, P., Toso, S., Di Liso, E., Ziampiri, S., Caccese, M., Zampiva, I., Puccetti, O., Celestino, M., Dieci, M. V., Conte, P.

مصطلحات موضوعية: Chemotherapy, COVID-19, Mortality, Patients with cancer, SARS-CoV-2 infection, Adult, Aged, 80 and over, Community Network, Disease Progression, Female, Hospital Mortality, Hospitalization, Human, Intensive Care Unit, Italy, Male, Middle Aged, Neoplasm, Pandemic, Prognosi, Registrie, SARS-CoV-2, Severity of Illness Index

الوصف: Introduction: Coronavirus disease 2019 (COVID-19) pandemic started in Italy with clusters identified in Northern Italy. The Veneto Oncology Network (Rete Oncologica Veneta) licenced dedicated guidelines to ensure proper care minimising the risk of infection in patients with cancer. Rete Oncologica Veneta covID19 (ROVID) is a regional registry aimed at describing epidemiology and clinical course of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with cancer. Materials and methods: Patients with cancer diagnosis and documented SARS-CoV-2 infection are eligible. Data on cancer diagnosis, comorbidities, anticancer treatments, as well as details on SARS-CoV-2 infection (hospitalisation, treatments, fate of the infection), have been recorded. Logistic regression analysis was applied to calculate the association between clinical/laboratory variables and death from any cause. Results: One hundred seventy patients have been enrolled. The median age at time of the SARS-CoV infection was 70 years (25–92). The most common cancer type was breast cancer (n = 40). The majority of the patients had stage IV disease. Half of the patients had two or more comorbidities. The majority of the patients (78%) presented with COVID-19 symptoms. More than 77% of the patients were hospitalized and 6% were admitted to intensive care units. Overall, 104 patients have documented resolution of the infection. Fifty-seven patients (33%) have died. In 29 cases (17%), the cause of death was directly correlated to SARS-CoV-2 infection. Factors significantly correlated with the risk of death were the following: Eastern Cooperative Oncology Group performance status (PS), age, presence of two or more comorbidities, presence of dyspnoea, COVID-19 phenotype ≥ 3, hospitalisation, intensive care unit admission, neutrophil/lymphocyte ratio and thrombocytopenia. Conclusions: The mortality rate reported in this confirms the frailty of this population. These data reinforce the need to protect patients with cancer from ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33647547; info:eu-repo/semantics/altIdentifier/wos/WOS:000631689400015; volume:147; firstpage:120; lastpage:127; numberofpages:8; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11577/3394806Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85101651036

الإتاحة: https://doi.org/10.1016/j.ejca.2021.01.021Test
http://hdl.handle.net/11577/3394806Test

المؤلفون: Ottaviano, M, Curvietto, M, Rescigno, P, Tortora, M, Palmieri, G, Giannarelli, D, Aieta, M, Assalone, P, Attademo, L, Avallone, A, Bloise, F, Bosso, D, Borzillo, V, Buono, G, Calderoni, G, Caputo, F, Cartenì, G, Cavallero, D, Cavo, A, Ciardiello, F, Conca, R, Conteduca, V, De Falco, S, De Felice, M, De Laurentiis, M, De Placido, P, De Placido, S, De Santo, I, De Stefano, A, Della Corte, CM, Di Franco, R, Di Lauro, V, Fabbrocini, A, Federico, P, Festino, L, Giordano, P, Giuliano, M, Gridelli, C, Grimaldi, AM, Lia, M, Marretta, AL, Massa, V, Mennitto, A, Merler, S, Merz, V, Messina, C, Messina, M, Milano, M, Minisini, AM, Montesarchio, V, Morabito, A, Morgillo, F, Mucci, B, Nappi, L, Napolitano, F, Paciolla, I, Pagliuca, M, Parola, S, Pepe, S, Petrillo, A, Piantedosi, F, Piccin, L, Picozzi, F, Pietroluongo, E, Pignata, S, Prati, V, Riccio, V, Rosanova, M, Rossi, A, Russo, A, Salati, M, Santabarbara, G, Sbrana, A, Simeone, E, Silvestri, A, Spada, M, Tarantino, P, Taveggia, P, Tomei, F, Vincenzo, T, Trapani, D, Trojanello, C, Vanella, V, Vari, S, Ventriglia, J, Vitale, MG, Vitiello, F, Vivaldi, C, von Arx, C, Zacchi, F, Zampiva, I, Zivi, A, Daniele, B, Ascierto, PA, SCITO (Società Campana di ImmunoTerapia Oncologica)

المساهمون: Rescigno, Pasquale

مصطلحات موضوعية: SCITO (Società Campana di ImmunoTerapia Oncologica), Humans, Pneumonia, Viral, Coronavirus Infections, Neoplasms, Prevalence, Medical Oncology, Infection Control, Geography, Adult, Italy, Female, Male, Drug Prescriptions, Pandemics, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Time-to-Treatment, Surveys and Questionnaires, Practice Patterns, Physicians', Oncologists, Betacoronavirus, Antineoplastic Agents, Immunological, B7-H1 Antigen, COVID-19, SARS-CoV-2

الوصف: BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region. METHODS: This survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2-positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher's exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options. RESULTS: This is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2-positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients' planned treatment approach). The results from responders in Campania did not differ significantly from the national ones. CONCLUSION: Our study highlights the efforts of Italian oncologists to maintain high standards of care ...

وصف الملف: Print; application/pdf

العلاقة: Journal for immunotherapy of cancer, 2020, 8 (2); https://repository.icr.ac.uk/handle/internal/4346Test

الإتاحة: https://doi.org/10.1136/jitc-2020-001154Test
https://repository.icr.ac.uk/handle/internal/4346Test

المؤلفون: Merler, S., Zuliani, S., Zampiva, I., Tregnago, D., Casali, M., Cavaliere, A., Fumagalli, A., Riva, S.T., Rossi, A., Zacchi, F., Zaninotto, E., Auriemma, A., Pavarana, M., Soldà, C., Benini, L., Borghesani, M., Lo Cascio, G., Tacconelli, E., Pilotto, S., Milella, M.

المصدر: Annals of Oncology ; volume 31, page S1011 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.1787Test
https://api.elsevier.com/content/article/PII:S0923753420417831?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420417831?httpAccept=text/plainTest

المؤلفون: Rebuzzi, S.E., Sternberg, C.N., Fornarini, G., Calabro', F., Baldessari, C., Scandurra, G., De Giorgi, U., Masini, C., Naglieri, E., Caserta, C., Galli, L., Maruzzo, M., Zampiva, I., Buttigliero, C., Astolfi, C., Banna, G.L.

المصدر: Annals of Oncology ; volume 31, page S592-S593 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.840Test
https://api.elsevier.com/content/article/PII:S0923753420408361?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420408361?httpAccept=text/plainTest

المؤلفون: Tregnago, D., Zuliani, S., Zampiva, I., Casali, M., Cavaliere, A., Fumagalli, A., Merler, S., Riva, S.T., Rossi, A., Zacchi, F., Zaninotto, E., Caldart, A., Casalino, S., Gaule, M., Kadrija, D., Mongillo, M., Rimondini, M., Del Piccolo, L., Milella, M., Pilotto, S.

المصدر: Annals of Oncology ; volume 31, page S1003 ; ISSN 0923-7534

مصطلحات موضوعية: Oncology, Hematology

الإتاحة: https://doi.org/10.1016/j.annonc.2020.08.1765Test
https://api.elsevier.com/content/article/PII:S0923753420417612?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753420417612?httpAccept=text/plainTest

المؤلفون: Bazzichetto C., Milella M., Zampiva I., Simionato F., Amoreo C. A., Buglioni S., Pacelli C., Le Pera L., Colombo T., Bria E., Zeuli M., Del Bufalo D., Sperduti I., Conciatori F.

المساهمون: Bazzichetto, C., Milella, M., Zampiva, I., Simionato, F., Amoreo, C. A., Buglioni, S., Pacelli, C., Le Pera, L., Colombo, T., Bria, E., Zeuli, M., Del Bufalo, D., Sperduti, I., Conciatori, F.

مصطلحات موضوعية: IL-8, advanced CRC, anti-angiogenic drug, chemotherapy, prognosi, tumor–stroma interactions

الوصف: Among soluble actors that have emerged as druggable factors, the chemokine interleukin-8 (IL-8) has emerged as a possible determinant of response to immunotherapy and targeted treatment in several cancer types; however, its prognostic/predictive role in colorectal cancer (CRC) remains to be established. We: (i) conducted a systematic review of published literature on IL-8 expression in CRC; (ii) searched public transcriptomics databases; (iii) investigated IL-8 expression, by tumor and infiltrating cells, in a series of CRC samples; and (iv) carried out a meta-analysis of published literature correlating IL-8 expression and CRC prognosis. IL-8 possesses an important role as a mediator of the bidirectional crosstalk between tumor/stromal cells. Transcriptomic analysis indicated that specific IL-8 transcripts were significantly overexpressed in CRC compared to normal colon mucosa. Moreover, in our series we observed a statistically significant correlation between PTEN-loss and IL-8 expression by infiltrating mononuclear and tumor cells. In total, 12 papers met our meta-analysis inclusion criteria, demonstrating that high IL-8 levels significantly correlated with shorter overall survival and progression-free survival. Sensitivity analysis demonstrated a highly significant correlation with outcome for circulating, but not for tissue-detected, IL-8. IL-8 is overexpressed in CRC tissues and differentially produced by tumor or stromal components depending on CRC genetic background. Moreover, circulating IL-8 represents a strong prognostic factor in CRC, suggesting its use in the refining of prognostic CRC assessment and potentially the tailoring of therapeutic strategies in individual CRC patients.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36289899; info:eu-repo/semantics/altIdentifier/wos/WOS:000872610900001; volume:10; issue:10; firstpage:2631; journal:BIOMEDICINES; https://hdl.handle.net/11573/1670563Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85140636787

الإتاحة: https://doi.org/10.3390/biomedicines10102631Test
https://hdl.handle.net/11573/1670563Test

المؤلفون: Masini C., Iotti C., De Giorgi U., Bellia R. S., Buti S., Salaroli F., Zampiva I., Mazzarotto R., Mucciarini C., Vitale M. G., Bruni A., Lohr F., Procopio G., Caffo O., Nole F., Morelli F., Baier S., Buttigliero C., Ciammella P., Timon G., Fantinel E., Carlinfante G., Berselli A., Pinto C.

المساهمون: Masini, C., Iotti, C., De Giorgi, U., Bellia, R. S., Buti, S., Salaroli, F., Zampiva, I., Mazzarotto, R., Mucciarini, C., Vitale, M. G., Bruni, A., Lohr, F., Procopio, G., Caffo, O., Nole, F., Morelli, F., Baier, S., Buttigliero, C., Ciammella, P., Timon, G., Fantinel, E., Carlinfante, G., Berselli, A., Pinto, C.

مصطلحات موضوعية: Abscopal effect, Kidney cancer, Metastatic, Nivolumab, Stereotactic body radiotherapy

الوصف: Background: Nivolumab showed an overall survival (OS) benefit in pretreated metastatic renal cell carcinoma (mRCC). The role of stereotactic body radiotherapy (SBRT) in mRCC remains to be defined. Objective: Our aim was to evaluate the efficacy and safety of SBRT in combination with nivolumab in second- and third-line mRCC patients. Design, setting, and participants: The NIVES study was a phase II, single-arm, multicenter trial in patients with mRCC with measurable metastatic sites who progressed after antiangiogenic therapy, of whom at least one was suitable for SBRT. Intervention: The patients received SBRT to a lesion at a dose of 10 Gy in three fractions for 7 d from the first infusion of nivolumab. Nivolumab was given at an initial dose of 240 mg every 14 d for 6 mo and then 480 mg q4-weekly in responding patients. Outcome measurements and statistical analysis: We hypothesized that nivolumab plus SBRT improves the objective response rate (ORR) compared with nivolumab alone from 25% (derived from historical controls) to 40%. Secondary endpoints were progression-free survival (PFS), OS, disease control rate (DCR) of irradiated and nonirradiated metastases, and safety. Results and limitations: Sixty-nine patients were enrolled from July 2017 to March 2019. The ORR was 17% and the DCR was 55%. The median PFS was 5.6 mo (95% confidence interval [CI], 2.9–7.1) and median OS 20 mo (95% CI, 17–not reached). After 1.5 yr of follow-up, 23 patients died. The median time to treatment response was 2.8 mo and median duration of response was 14 mo. No new safety concerns arose. Conclusions: We did not find sufficient evidence to suggest that nivolumab in combination with SBRT provides an added benefit in pretreated mRCC patients; it should however be evaluated in patients with oligometastatic or oligoprogressive disease. Patient summary: Nivolumab in combination with stereotactic body radiotherapy does not provide evidence of increased outcomes in metastatic renal cell carcinoma patients. However this approach was safe ...

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000809752100018; journal:EUROPEAN UROLOGY; http://hdl.handle.net/11381/2913694Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85116170305

الإتاحة: https://doi.org/10.1016/j.eururo.2021.09.016Test
http://hdl.handle.net/11381/2913694Test

المؤلفون: Caldart, A., Fiorio, E., Zanelli, S., Biondani, P., Parolin, V., Pellini, F., Montemezzi, S., Nottegar, A., Caliò, A., Zampiva, I., Merler, S., Mongillo, M., Avesani, B., Borghesani, G., Giontella, E., Scarpa, A., Milella, M.

المصدر: European Journal of Cancer ; volume 175, page S38-S39 ; ISSN 0959-8049

مصطلحات موضوعية: Cancer Research, Oncology

الإتاحة: https://doi.org/10.1016/s0959-8049Test(22)01453-8
https://api.elsevier.com/content/article/PII:S0959804922014538?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0959804922014538?httpAccept=text/plainTest